Premium
Effects of Esomeprazole on the Pharmacokinetics of Atazanavir and Fosamprenavir in a Patient with Human Immunodeficiency Virus Infection
Author(s) -
Kiser Jennifer J.,
Lichtenstein Kenneth A.,
Anderson Peter L.,
Fletcher Courtney V.
Publication year - 2006
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.26.4.511
Subject(s) - esomeprazole , ritonavir , atazanavir , pharmacokinetics , medicine , pharmacology , viral load , human immunodeficiency virus (hiv) , virology , gastroenterology , antiretroviral therapy
The effects of proton pump inhibitors on the pharmacokinetics of atazanavir and amprenavir (administered as fosamprenavir) were rigorously evaluated in healthy volunteers in two studies, but formal studies in persons infected with human immunodeficiency virus (HIV) are lacking. We describe a 65‐year‐old man with HIV who underwent a 12‐hour intensive pharmacokinetic study while receiving esomeprazole with atazanavir‐ritonavir and subsequently, an 8‐hour study while receiving esomeprazole with fosamprenavir‐ritonavir. Consistent with the data in healthy volunteers, a major interaction between esomeprazole and atazanavir‐ritonavir was observed in this patient—marked reductions in atazanavir trough plasma concentration and in the area under the concentration‐time curve from 0–24 hours—whereas an interaction between esomeprazole and fosamprenavir‐ritonavir was not apparent in this patient.